Patients at high risk of bleeding after receiving a drug-eluting stent should undergo 1 month of dual antiplatelet therapy (DAPT) followed by single antiplatelet therapy (SAPT), a principal investigator of the MASTER DAPT trial said Saturday at the virtual European Society of Cardiology (ESC) Congress 2021.